391 related articles for article (PubMed ID: 8967979)
21. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
[TBL] [Abstract][Full Text] [Related]
22. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
23. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
24. New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.
Berardi F; Colabufo NA; Giudice G; Perrone R; Tortorella V; Govoni S; Lucchi L
J Med Chem; 1996 Jan; 39(1):176-82. PubMed ID: 8568804
[TBL] [Abstract][Full Text] [Related]
25. Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding.
Wurch T; Colpaert FC; Pauwels PJ
Mol Pharmacol; 1998 Dec; 54(6):1088-96. PubMed ID: 9855638
[TBL] [Abstract][Full Text] [Related]
26. The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT1B/1D receptors.
De Vries P; Willems EW; Heiligers JP; Villalón CM; Saxena PR
Eur J Pharmacol; 1998 Jun; 351(2):193-201. PubMed ID: 9687003
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Napier C; Stewart M; Melrose H; Hopkins B; McHarg A; Wallis R
Eur J Pharmacol; 1999 Mar; 368(2-3):259-68. PubMed ID: 10193663
[TBL] [Abstract][Full Text] [Related]
28. Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration.
Piñeyro G; Blier P
J Pharmacol Exp Ther; 1996 Feb; 276(2):697-707. PubMed ID: 8632339
[TBL] [Abstract][Full Text] [Related]
29. [3H]dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5-HT1B binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states.
Hamblin MW; Ariani K; Adriaenssens PI; Ciaranello RD
J Pharmacol Exp Ther; 1987 Dec; 243(3):989-1001. PubMed ID: 2826763
[TBL] [Abstract][Full Text] [Related]
30. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
31. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
32. Differential inactivation and G protein reconstitution of subtypes of [3H]5-hydroxytryptamine binding sites in brain.
Stratford CA; Tan GL; Hamblin MW; Ciaranello RD
Mol Pharmacol; 1988 Oct; 34(4):527-36. PubMed ID: 3139989
[TBL] [Abstract][Full Text] [Related]
33. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor.
Pauwels PJ; Wurch T; Palmier C; Colpaert FC
Br J Pharmacol; 1998 Jan; 123(1):51-62. PubMed ID: 9484854
[TBL] [Abstract][Full Text] [Related]
35. Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.
Brys R; Josson K; Castelli MP; Jurzak M; Lijnen P; Gommeren W; Leysen JE
Mol Pharmacol; 2000 Jun; 57(6):1132-41. PubMed ID: 10825383
[TBL] [Abstract][Full Text] [Related]
36. The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist.
Rënyi L; Evenden JL; Fowler CJ; Jerning E; Kelder D; Lake-Bakaar D; Larsson LG; Mohell N; Sällemark M; Ross SB
J Pharmacol Exp Ther; 2001 Dec; 299(3):883-93. PubMed ID: 11714872
[TBL] [Abstract][Full Text] [Related]
37. Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype.
Zgombick JM; Weinshank RL; Macchi M; Schechter LE; Branchek TA; Hartig PR
Mol Pharmacol; 1991 Dec; 40(6):1036-42. PubMed ID: 1758439
[TBL] [Abstract][Full Text] [Related]
38. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
Selkirk JV; Scott C; Ho M; Burton MJ; Watson J; Gaster LM; Collin L; Jones BJ; Middlemiss DN; Price GW
Br J Pharmacol; 1998 Sep; 125(1):202-8. PubMed ID: 9776361
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterizations of recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes.
Zgombick JM; Schechter LE; Adham N; Kucharewicz SA; Weinshank RL; Branchek TA
Naunyn Schmiedebergs Arch Pharmacol; 1996; 354(3):226-36. PubMed ID: 8878051
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation.
Adham N; Zgombick JM; Bard J; Branchek TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):508-14. PubMed ID: 9808674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
